Centiva Capital, LP Neurocrine Biosciences Inc Transaction History
Centiva Capital, LP
- $4.79 Billion
- Q3 2024
A detailed history of Centiva Capital, LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Centiva Capital, LP holds 2,079 shares of NBIX stock, worth $243,617. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,079
Previous 2,821
26.3%
Holding current value
$243,617
Previous $388,000
38.4%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
643Shares Held
94.7MCall Options Held
615KPut Options Held
570K-
Black Rock Inc. New York, NY14.2MShares$1.66 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.19 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$603 Million0.02% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$353 Million0.26% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.49MShares$292 Million0.54% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...